Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 16 August 2024, including: Merck & Co., Inc. steps into CD19 bispecific space; gene therapy patients rise, but slowly; Madrigal Pharmaceuticals, Inc.’s Rezdiffra plans; Korean biopharma financing recovering?; and approvals to watch out for in Q3.
This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Merck Steps Into CD19 Bispecific Antibody Ring With Curon Deal" - Scrip, 9 August, 2024.)
(Also see "Gene Therapy Patient Pipeline Builds, But Slowly, In Q2" - Scrip, 14 August, 2024.)
(Also see "Madrigal Likes Rezdiffra’s Long-Term Positioning In NASH" - Scrip, 9 August, 2024.)
(Also see "Korean Biopharma Financings Remain In Doldrums But Recovery In Sight?" - Scrip, 13 August, 2024.)
(Also see "10 Approvals To Watch Out For In Q3" - Scrip, 9 August, 2024.)
